GSK PLC Sponsored ADR $GSK Shares Sold by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company reduced its holdings in GSK PLC Sponsored ADR by 15.2%, selling 200,705 shares, and now owns 1,118,094 shares valued at approximately $43.3 million.
• GSK reported $1.23 earnings per share, surpassing analysts' expectations of $1.12, with quarterly revenues of $10.64 billion, significantly above the forecast of $7.92 billion.
• The company recently announced a quarterly dividend of $0.4206 per share, yielding 4.2%, and its payout ratio stands at 77.78%.

The Manufacturers Life Insurance Company lowered its position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 15.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,118,094 shares of the pharmaceutical company's stock after selling 200,705 shares during the period. The Manufacturers Life Insurance Company owned about 0.05% of GSK worth $43,315,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Dodge & Cox raised its position in GSK by 14.9% during the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock valued at $3,046,972,000 after purchasing an additional 10,210,921 shares during the last quarter. Voloridge Investment Management LLC grew its stake in shares of GSK by 1,360.4% in the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after buying an additional 2,016,795 shares during the last quarter. Woodline Partners LP purchased a new stake in shares of GSK in the 4th quarter worth approximately $36,665,000. Miller Howard Investments Inc. NY boosted its stake in GSK by 138.4% during the 1st quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock valued at $63,797,000 after purchasing an additional 955,891 shares during the last quarter. Finally, Kahn Brothers Group Inc. purchased a new stake in GSK during the 4th quarter valued at $29,921,000. Institutional investors own 15.74% of the company's stock.

GSK Stock Up 0.5%

NYSE:GSK traded up $0.19 during trading hours on Thursday, reaching $39.55. The company's stock had a trading volume of 2,935,645 shares, compared to its average volume of 5,079,798. The stock has a 50 day moving average price of $38.46 and a two-hundred day moving average price of $38.28. The company has a debt-to-equity ratio of 1.07, a quick ratio of 0.57 and a current ratio of 0.87. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.19. The company has a market capitalization of $80.56 billion, a P/E ratio of 18.31, a price-to-earnings-growth ratio of 1.72 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. During the same period in the previous year, the company earned $0.43 earnings per share. The business's quarterly revenue was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analyst Ratings Changes

GSK has been the topic of several research analyst reports. Wall Street Zen raised GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, GSK presently has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.